Palbociclib (CAS 571190-30-2) is a selective inhibitor of cyclin-dependent kinases CDK4 and CDK6, which control cell cycle progression. Known in research as PF-00080665, this compound plays an important role in studies focused on cancer cell proliferation and targeted therapeutic strategies. The palbociclib cas number is widely referenced in biochemical databases, while identifiers such as 571190-30-2 cas and cas 571190-30-2 are commonly used in laboratory procurement and research documentation.
Researchers frequently investigate the palbociclib chemical structure to better understand its interaction with kinase domains responsible for regulating the cell cycle. The compound has a defined palbociclib molecular formula and stable physicochemical properties suitable for experimental use. Laboratories involved in oncology research often buy 571190-30-2 to study cell cycle regulation and to evaluate new approaches for inhibiting uncontrolled tumor cell proliferation.
Application of Palbociclib
Palbociclib is widely used in biomedical research investigating mechanisms of cell cycle control and cancer development. By selectively inhibiting CDK4 and CDK6, the compound allows researchers to study signaling pathways that regulate cell division and tumor growth.
- Research on CDK4/CDK6 signaling pathways
- Investigation of tumor cell cycle regulation
- Screening and validation of cell cycle inhibitors
- Studies of targeted cancer therapies
In Vitro
In vitro studies show that Palbociclib effectively blocks CDK4/6 activity, preventing phosphorylation of the retinoblastoma protein (Rb) and thereby stopping cell cycle progression at the G1 phase. This inhibition reduces proliferation of cancer cell lines that rely on CDK4/6 signaling for growth, making Palbociclib a valuable reference compound for experimental oncology studies.
In Vivo
In vivo models have demonstrated that CDK4/6 inhibition can suppress tumor growth by limiting uncontrolled cell division. Studies involving PF-00080665 help researchers investigate how cell cycle inhibition influences tumor progression and therapeutic response in preclinical cancer models.
Biochemical and Physiological Actions
The biochemical activity of Palbociclib involves selective inhibition of cyclin-dependent kinases CDK4 and CDK6. By blocking phosphorylation events required for cell cycle progression, the compound interferes with molecular pathways responsible for uncontrolled cellular proliferation.
Features and Benefits of Palbociclib
- Selective inhibitor of CDK4 and CDK6 kinases
- Important tool for studying cell cycle regulation
- Widely used in oncology and kinase signaling research
- Applicable in both in vitro and in vivo experimental models
High-quality bioactive compounds enable researchers to explore molecular targets and signaling pathways with greater precision. Access to validated reference molecules supports drug discovery programs and helps scientists better understand mechanisms involved in cancer biology and targeted therapy development.
